Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

The Joint Corp. JYNT

Healthcare — Medical Care Facilities
Insider Buys (last 12m)
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
1.98
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — 1 3 2 2 — 1 1 — — — —
Sell — — — — — — — — — — — —
Insider Ownership
16.81%

Capital & Financial Ratios

Market Cap
119.23
Revenue
58.55
Net Income
3.80
Free Cash Flow
4.23
Net Debt
(23.00)
Current Ratio
1.83
Debt/Equity
0.00
P/E ratio
31.26
P/S ratio
2.05
P/B ratio
7.57
Past 5Y EPS Growth
—
This Y EPS Growth
1,300.00%
Next Y EPS Growth
63.89%
Next 5Y EPS Growth
25.00%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 19.21 26.00 24.30 23.00
Receivables 2.58 2.59 2.85 2.41
Inventory — — — —
Other 17.92 — — —
44.34 74.58 52.09 43.80
2023 2024 2025 Q'26
Payables 1.25 1.75 1.59 1.10
ST’ Debt — — — —
Other 2.77 5.39 5.64 3.81
33.57 49.04 32.82 23.98
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 14.82 15.18 — —
—
’25 13.08 13.27 13.38 15.17
54.90
’24 12.18 12.61 12.65 14.71
52.16
’23 28.30 29.31 29.47 (40.10)
46.98
’22 22.24 24.89 26.45 27.68
101.25
’21 17.55 20.22 20.99 21.25
80.01
’20 13.64 12.59 15.41 17.04
58.68
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (1.48) 2.19 — —
—
’25 (3.70) 0.87 1.77 2.90
1.84
’24 2.81 (0.97) 3.45 4.13
9.42
’23 6.02 1.47 3.80 3.38
14.68
’22 0.20 (1.38) 4.22 5.18
8.21
’21 2.27 6.74 3.44 1.39
13.84
’20 1.47 1.56 3.87 4.28
11.18
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (1.71) 1.94 — —
—
’25 (4.03) 0.36 1.46 2.55
0.33
’24 2.42 (1.24) 3.20 3.85
8.23
’23 4.82 (0.06) 2.70 2.22
9.68
’22 (1.09) (5.66) 0.41 3.38
2.31
’21 (0.07) 4.46 1.29 (0.21)
6.85
’20 0.21 0.84 3.51 2.42
6.99
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.09 0.05 — —
—
’25 0.05 0.01 0.06 0.07
0.19
’24 0.06 (0.24) (0.21) (0.18)
(0.56)
’23 0.15 (0.01) (0.05) (0.75)
(0.65)
’22 (0.01) 0.02 0.03 0.04
0.08
’21 0.16 0.18 0.13 0.01
0.48
’20 0.06 0.01 0.11 0.72
0.90

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡
Low
‡‡‡‡‡
‡‡‡

Recommendation Rating

2.5
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 12.85 7.31 8.88 7.50 — — —
Low Price
‡‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 66.42 20.00 17.82 13.47 — — —
High Price
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 781 794 736 330 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.13 0.06 0.07 0.17 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 101.25 46.98 52.16 54.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 90.94% 77.69% 77.92% 79.55% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.70 0.25 (1.61) (0.23) ‡‡‡‡‡ — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.69% 0.54% (3.08%) (0.42%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.63 (9.75) (5.80) 2.91 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.65 8.58 4.72 1.71 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.99 3.20 3.50 3.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡ 0.08 (0.66) (0.57) 0.19 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.57 1.00 0.63 0.12 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.41) (0.34) (0.08) (0.10) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.16 0.66 0.55 0.02 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.25 1.69 1.39 1.00 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 14.49 14.69 14.92 15.13 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 172.13 0.00 0.00 45.89 ‡‡‡‡ ‡‡‡‡ —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.97 2.95 3.04 2.40 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 6.12 5.60 7.67 8.75 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.94 2.70 2.65 2.06 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (66.23) 28.84 46.72 (22.89) — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.21 14.68 9.42 1.84 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.90) (5.00) (1.19) (1.50) ‡‡‡‡‡ — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.31 9.68 8.23 0.33 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (5.60) 10.76 25.54 19.27 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.38 2.00 — — — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (3.17) (17.21) (26.00) (24.30) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 32.59 24.77 20.68 15.08 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.69% (10.79%) (6.81%) 4.03% ‡‡‡‡‡ — —
ROA
‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.76% 2.63% 0.00% 0.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.99% (34.00%) (25.51%) 16.26% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

The Joint Corp. (JYNT), a premier franchisor of chiropractic clinics, delivered explosive growth from 2016-2022 with revenue compounding at 30% CAGR to $101.3 million and stock soaring over 1,750% to $111, fueled by franchise expansion and peak productivity (revenue/employee at $323,000 in 2019). However, 2023 marked a sharp reversal—revenue halved to $47 million, net income swung to a $9.8 million loss, and shares plunged 82%—exposing vulnerabilities in fixed costs and consumer spending amid post-pandemic normalization.

Emerging signals point to stabilization and rebound: 2024 revenue rose 11% to $52.2 million, FCF/share yielded ~6%, and insiders scooped up $936,000 in shares (zero sells) at $8-16 levels. Analysts forecast net income recovery to $8.8 million by 2026 (+452% from 2024), with price targets implying 4% mean upside (61% to high) and revenue edging to $56.3 million by 2027.

At current multiples (PS ~3x, forward PE 15-64x), JYNT trades as a discounted recovery play with resilient 88-90% historical margins, positive cash flows, and quant models assigning 65% odds of 20%+ returns in 12 months—hinging on margin repair, wellness demand, and execution amid macro risks.

Read full commentary →

The Joint Corp. (JYNT) Latest News

News by impact score

Fine-tune

13 Aug

4 transcript www.fool.com, 6:15 PM
Joint Corp (JYNT) Q2 2026 earnings call transcript covers financial results, operations and outlook. Q2 earnings disclosure and forward commentary directly influence JYNT valuation and sentiment.

7 Aug

4 transcript app.moby.co, 8:30 AM
The Joint Corp. (JYNT) released its Q2 2026 earnings call summary covering financial results, system-wide sales, clinic growth, and management outlook. Q2 earnings call and guidance directly shape near-term valuation and investor positioning for JYNT.

4 transcript , 1:03 AM
The Joint Corp nears completion of refranchising as detailed in its Q2 2026 earnings call highlights. Refranchising nearing completion marks a major strategic shift likely to alter operations and investor outlook.

3 www.marketbeat.com, 12:03 AM
Joint Corp. (JYNT) released Q2 earnings call highlights. Q2 earnings highlights provide performance details that moderately influence market perception and operations.

6 Aug

3 , 7:10 PM
The Joint Corp. (JYNT) posted a Q2 loss but exceeded revenue estimates. Q2 loss with revenue beat may moderately influence financial performance and investor sentiment.

3 , 4:05 PM
The Joint Corp. (JYNT) released its second quarter 2026 financial results. Quarterly earnings provide moderate insight into financial performance and near-term outlook.

8 May

4 www.marketbeat.com, 1:07 AM
The Joint Corp. (JYNT) reported Q1 revenue of $32.1 million, up 17% year-over-year, with system-wide sales at $62.3 million, up 12%. Same-store sales grew 3.2%, clinic count reached 447 with 21 net new openings. Adjusted EBITDA rose 35% to $4.8 million. Full-year guidance reaffirmed: revenue $130-132 million, EBITDA $18-19 million. Management highlighted franchise expansion and membership growth. Strong Q1 revenue growth, EBITDA expansion, and reaffirmed guidance signal robust operational momentum and positive trajectory for JYNT.

7 May

4 Zacks, 10:25 PM
The Joint Corp. (JYNT) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates boosts financial performance and investor sentiment significantly.

4 app.moby.co, 8:39 PM
The Joint Corp. (JYNT) Q1 2026 earnings call summary details financial results, operational updates, and forward guidance. Q1 2026 earnings results and guidance significantly influence JYNT's financial trajectory and investor sentiment.

3 , 4:05 PM
The Joint Corp. (JYNT) reported first quarter 2026 financial results. Quarterly earnings reports typically affect financial performance and market sentiment moderately.

27 Apr

4 GlobeNewswire, 4:05 PM
The Joint Corp. (JYNT) signed an asset purchase agreement to sell 45 corporate-owned clinics in Southern California. Selling 45 corporate-owned clinics is a major strategic move that could refocus operations on franchising and boost profitability.

29 Mar

4 Simply Wall St., 8:16 AM
Loss-making The Joint Corp. (NASDAQ:JYNT) is set to breakeven, signaling a turnaround from persistent unprofitability. Breakeven achievement for a loss-making company represents a major financial milestone that could significantly boost investor sentiment and stock trajectory.

13 Mar

4 app.moby.co, 8:30 AM
The Joint Corp. (JYNT) released Q4 2025 earnings call summary highlighting financial results, operational updates, and future outlook. Q4 earnings call summary reveals financial performance and guidance that significantly shape investor sentiment and stock trajectory.

12 Mar

4 GuruFocus.com, 11:04 PM
The Joint Corp. (JYNT) Q4 2025 earnings call highlights strategic refranchising to boost profitability, enhanced marketing for patient acquisition, and operational improvements amid revenue growth and clinic expansion. Strategic refranchising and marketing initiatives represent major moves to enhance profitability and growth trajectory.

4 www.marketbeat.com, 8:46 PM
The Joint Corp. (JYNT) released highlights from its Q4 earnings call, covering financial performance, operational updates, and forward-looking guidance. Q4 earnings call highlights disclose key financial results and strategic outlook, poised to significantly sway investor sentiment and stock trajectory.

4 transcript www.fool.com, 6:39 PM
The Joint Corp. (JYNT) Q4 2025 earnings call transcript details quarterly financial results, operational updates, and forward guidance. Q4 earnings call transcript reveals financial performance and strategic outlook with significant potential to alter JYNT's trajectory and investor sentiment.

4 Zacks, 6:30 PM
The Joint Corp. (JYNT) beat Q4 earnings and revenue estimates. Beating Q4 earnings and revenue estimates indicates strong financial results likely to enhance investor sentiment and stock performance.

4 GlobeNewswire, 4:05 PM
The Joint Corp. (JYNT) reported fourth quarter and full-year 2025 financial results. Quarterly and full-year earnings releases reveal key financial metrics like revenue and profitability that significantly sway investor sentiment and stock trajectory.

16 Jan

3 Simply Wall St., 9:37 AM
The Joint Corp. (JYNT) is analyzed for its intrinsic value, focusing on its financial performance, growth potential, and market position. The article evaluates key metrics and compares them to industry standards, providing insights into the company's valuation. Factors such as revenue growth, profitability, and market trends are discussed to assess JYNT's future prospects and investment potential. Moderate influence on financial performance and market sentiment is expected based on the analysis of intrinsic value and growth potential.

5 Jan

3 GlobeNewswire, 4:05 PM
The Joint Corp. has appointed Ron Stilwell as Senior Vice President of Operations and Patient Experience. Stilwell brings over 25 years of experience in operations and management, having previously held leadership roles in various healthcare organizations. His expertise is expected to enhance operational efficiency and improve patient experiences at The Joint Corp., which specializes in chiropractic care. The appointment of a seasoned executive like Ron Stilwell is likely to moderately influence operational effectiveness and patient satisfaction, impacting the company's performance.

24 Dec

3 Simply Wall St., 6:34 AM
The Joint Corp. (JYNT) is facing challenges in effectively utilizing its capital, which may hinder its growth and operational efficiency. Despite its expansion efforts, the company struggles with financial management and investment strategies, raising concerns among investors about its future performance and market positioning. Ineffective capital utilization may moderately influence financial performance and investor sentiment.

11 Dec

3 GlobeNewswire, 4:52 PM
The Joint Corp. has signed an asset purchase agreement to sell 22 corporate clinics located in the Southeast. Additionally, the company has delivered a notice to terminate the asset purchase agreement for 45 clinics in California, indicating a strategic shift in its operations. The sale and termination of clinics may moderately influence The Joint Corp.'s financial performance and operational strategy.

3 Dec

4 Simply Wall St., 12:50 PM
Insiders at The Joint Corp. purchased a total of US$509.3k in stock, signaling strong confidence in the company's future. This buying activity, particularly by key executives, often indicates a positive outlook on the company's performance and potential growth. Such insider transactions can influence market sentiment and investor confidence, suggesting that insiders believe the stock is undervalued or that the company is poised for success. Insider buying of this magnitude typically reflects strong confidence in the company's future performance and can significantly influence investor sentiment.

17 Nov

3 Zacks, 10:36 AM
Options traders are showing increased activity in The Joint Corp. (JYNT), indicating expectations of a significant price movement in the stock. The heightened volume of options trading suggests that investors are anticipating volatility, which could be driven by upcoming earnings reports or market developments. Analysts are closely monitoring these trends to gauge potential impacts on the company's stock performance. Increased options trading activity suggests potential volatility that may influence market sentiment and stock performance.

13 Nov

3 Simply Wall St.MT NewswiresSimply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St.Simply Wall St., 5:20 AM
The Joint Corp. (JYNT) is experiencing a potential shift in market dynamics, prompting discussions about whether now is an opportune time for investors to consider purchasing shares. Analysts are evaluating the company's recent performance, growth strategies, and market conditions that could influence its future trajectory. The focus is on how these factors may impact investor sentiment and the overall valuation of the company in the chiropractic care sector. Current market evaluations and growth strategies may moderately influence The Joint Corp.'s financial performance and competitive positioning.

7 Nov

4 GuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.comGuruFocus.com, 12:09 AM
The Joint Corp. (JYNT) reported its Q3 2025 earnings, highlighting a strategic refranchising initiative aimed at enhancing revenue and operational efficiency. The company emphasized its commitment to expanding its franchise model, which is expected to drive growth and improve financial performance. Key metrics showed positive trends, indicating a solid demand for chiropractic services. Management expressed optimism about future prospects and outlined plans for continued expansion in the coming quarters. Strategic refranchising and revenue growth initiatives are likely to significantly impact future performance and investor sentiment.

6 Nov

4 Zacks, 8:05 PM
The Joint Corp. (JYNT) reported better-than-expected earnings and revenue for Q3, surpassing analysts' estimates. The company's performance reflects strong demand for its chiropractic services and effective operational strategies. This positive financial outcome indicates robust growth potential and may enhance investor confidence in the company's future prospects. Strong earnings and revenue growth suggest significant positive momentum for the company's future performance.

4 , 4:05 PM
The Joint Corp. reported its financial results for the third quarter of 2025, highlighting a significant increase in revenue and patient visits compared to the previous year. The company attributed its growth to expanded clinic locations and enhanced marketing efforts. Additionally, The Joint Corp. announced plans for further expansion and investment in technology to improve patient care. Overall, the results reflect a positive trajectory for the company amidst a competitive landscape. The reported financial growth and expansion plans indicate a significant impact on future performance and market positioning.

5 Nov

3 GlobeNewswire, 7:05 AM
The Joint Corp. has authorized an additional $12 million for its stock repurchase program, reflecting the company's commitment to returning value to shareholders. This move is part of a broader strategy to enhance shareholder equity and manage capital effectively. The stock repurchase program is expected to moderately influence investor sentiment and financial performance.

23 Oct

3 GlobeNewswire, 7:05 AM
The Joint Corp. will host a conference call on November 6th to discuss its third quarter 2025 results, providing an opportunity for investors and analysts to gain insights into the company's financial performance and strategic direction. The conference call may provide insights that could moderately influence investor sentiment and financial performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us